BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly to $565 from $505 and keeps an Outperform rating on the shares ahead of the Q2 print. The firm expects Mounjaro to be the central focus of the earnings call, where the company may offer commentary around capacity ahead of likely approval in obesity later this year, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LLY: